WIN-CONSORTIUM
17.5.2019 11:40:10 CEST | Business Wire | Press release
The 11th WIN Symposium in Precision Oncology will be held in Paris, France on June 23-24, 2019.
ASCO® endorsed for the past 11 years, the WIN symposium will deliver an
exciting line-up of speakers in Paris (France) on June 23-24, 2019 to
discuss Innovation and Global Deployment of Precision Oncology.
The
current status of Precision Oncology across the globe will be examined
with the exceptional participation of the chairmen of the event, Richard
L. Schilsky, Chairman WIN Consortium(*)
, Senior
Vice-President and Chief Medical Officer of ASCO, and Josep Tabernero,
Vice Chairman WIN Consortium, President of ESMO and Director of Vall
d’Hebron Institute of Oncology, Spain.
Global experience will be shared:
- Optimizing Patient Enrollment and Efficacy of Precision Oncology Clinical Trials at UT MD Anderson Cancer Center, USA
- Decision Support for Precision Oncology: Evolving from Monotherapy to Genomically Informed Combinations, UT MD Anderson Cancer Center, USA
- The Value of Personalized Medicines for Healthcare Systems in Europe – by the European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA)
- Rapidly changing landscape of Precision Medicine in Japan, Tokyo Medical and Dental University
- National Cancer Grid of India – Earthshots over Moonshots, TATA Memorial Hospital
- Development and Application of Precision Oncology in China, Fudan University Shanghai Cancer Center
World leading precision oncologists will deliver breakthrough science, including:
- Prof. Jennifer A. Doudna, PhD, University of California, Berkeley, USA “Rewriting the Code of Life: CRISPR-Cas Genome Editing”.
- Dr. Jennifer A. Ligibel, MD, Harvard Medical School and Dana Farber Cancer Institute, USA “Lifestyle-based Prevention Strategies”.
- Dr. Razelle Kurzrock, MD, University of California, San Diego, USA, “Innovation in Clinical Trials: WINTHER trial”, first study pioneered by the WIN Consortium (*) , that showed that assessing RNA is an important adjunct to DNA profiling for determining treatments and rings in a new era for personalized medicine in oncology. WINTHER results were recently published in Nature Medicine (**)
- Prof. Christophe Le Tourneau, MD., PhD, Institut Curie, France, “Innovative Ways of Assessing Durable Response under Immunotherapy”
- Dr. Jean François Martini, PhD., MSc, Pfizer Inc., “Addressing Mechanisms of Resistance Following Anti-Cancer Therapy: a Pharma Perspective”
- Prof. Angel Porgador, PhD, Ben Gurion University of Negev, Israel, “Efficient In Vitro Screening for Drug Combinations: The TEVA Model”
Do not miss the two microsatellites hosted at the WIN Symposium:
- Real-World Evidence and its Relevance for Clinical Practice and Stakeholder Decision Making - F. Hoffmann-La Roche Ltd
- Artificial Intelligence to Support Patient Profiling in Precision Oncology - Definiens AG
The WIN symposium provides outstanding networking opportunities for all professionals in cancer care.
(*) WIN Consortium is a non-profit organization based in Paris, France. We are a worldwide network assembling cancer stakeholders from four continents to develop cutting edge concepts and clinical trials that improve survival for cancer patients. WIN members include 28 outstanding cancer centers plus 11 additional leading pharmaceutical, technology companies and patient advocacy organizations representing stakeholders in precision cancer medicine, www.winconsortium.org
(**) Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial https://doi.org/10.1038/s41591-019-0424-4
For more information: www.winsymposium.org
ASCO® is a registered trademark of the American Society of Clinical Oncology®. Used with permission. This is not an ASCO sponsored event.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190517005150/en/
Contact:
WIN Consortium Vladimir Lazar Chief Scientific and Operating Officer vladimir.lazar@winconsortium.org Telephone: + 33 66 109 15 22
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DCO Concludes 5th General Assembly with Adoption of the Kuwait Declaration on Responsible AI for Global Digital Prosperity7.2.2026 16:41:00 CET | Press release
The Digital Cooperation Organization (DCO) has concluded its fifth General Assembly, with Member States adopting the Kuwait Declaration on Responsible AI for Global Digital Prosperity and agreeing on actions to advance inclusive, trusted, and scalable digital transformation in the AI age. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260207972901/en/ DCO concludes 5th General Assembly with adoption of the Kuwait Declaration on Responsible AI for Global Digital Prosperity (Photo: AETOSWire) Convened on 4–5 February 2026 under the Presidency of the State of Kuwait, the General Assembly brought together Ministers and Representatives of Member States, alongside Observers, partners, and guest countries, to review progress against the DCO 4-Year Agenda (2025–2028), take joint decisions on multilateral initiatives, and translate shared ambition on AI into delivery. Ministers and representatives reaffirmed their commitment to inclu
Rapid Medical™’s DISTALS Trial Overwhelmingly Positive, Demonstrating Superior Reperfusion with TIGERTRIEVER™ 13 in Medium Vessel Stroke6.2.2026 20:30:00 CET | Press release
TIGERTRIEVER™ 13 is the first device shown to meet safety and effectiveness endpoints for restoring blood flow in smaller but critical areas of the brain, accounting for almost 50% of all ischemic strokes Rapid Medical™, a leading developer of active endovascular devices, today announced late-breaking results from the DISTALS multicenter, randomized controlled trial showing that TIGERTRIEVER™ 13 achieved superior brain tissue reperfusion with an excellent safety profile when compared with medical management in medium vessel occlusion (MVO) stroke. The findings were presented in the main closing session at the 2026 International Stroke Conference (ISC). Top-line results showed that the TIGERTRIEVER™ 13 arm demonstrated 3x more successful reperfusion without symptomatic intracranial hemorrhage (sICH) compared to medical management–86.3% vs 27.7% (p < 0.001). Notably, zero sICH events were reported in the randomized treatment arm treated with TIGERTRIEVER 13. By comparison, sICH rates rep
Al Barari Breaks Ground on The Cape, The Final Chapter of a Legacy6.2.2026 15:46:00 CET | Press release
Al Barari, Dubai’s pioneering nature-led community, has officially marked the groundbreaking of The Cape, its final signature residential development, celebrating two decades of visionary craftsmanship and a continued commitment to creating harmonious living environments rooted in nature. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260206475199/en/ Hazza Zaal, CEO of Al Barari Real Estate Group, alongside the Sales and Construction teams at The Cape Groundbreaking Ceremony, marking a milestone in Al Barari’s final signature development. (Photo: AETOSWire) The milestone ceremony signals the beginning of a landmark chapter for Al Barari, as The Cape represents the culmination of a 20-year legacy defined by intentional design, wellbeing-focused living, and immersive natural landscapes. Located within Dubai’s green heart, The Cape introduces an enriched lifestyle experience surrounded by lush botanical settings, gentle water
Andersen Consulting indgår samarbejdsaftale med Alfa Group6.2.2026 15:41:00 CET | Pressemeddelelse
Andersen Consulting styrker sit udbud inden for cybersikkerhed gennem samarbejdet med Alfa Group, der er en førende teknologivirksomhed med næsten tre årtiers erfaring i at hjælpe organisationer med at beskytte og optimere deres drift. Alfa Group blev grundlagt i 1996 og har hovedsæde i Rom. Virksomheden leverer avancerede løsninger inden for cybersikkerhed, registrering og forebyggelse af svindel, hændelseshåndtering og sårbarhedsstyring samt udvalgte ydelser inden for processtyring. Deres proprietære teknologi, N.O.V.A., er en fuldt integreret administreret tjeneste, der kombinerer Alfa Groups innovationer med tredjepartssystemer for at beskytte digitale infrastrukturer, reducere risici og øge den operationelle effektivitet. Virksomheden betjener kunder på tværs af brancher, herunder finans og forsikring, forsvar og rumfart, telekommunikation, fremstilling, energi og medicinalindustrien. "Vores samarbejde med Andersen Consulting giver os mulighed for at udvide vores rækkevidde og lev
Quantfury and Sandwich Launch Commercial Series to Encourage Better Choices in Retail Trading6.2.2026 15:00:00 CET | Press release
Quantfury Trading Americas Limited (“Quantfury”), a global brokerage offering commission-free trading at real-time spot prices from major exchanges, has partnered with Sandwich, a leading creative agency for tech and product videos, to produce a Social Responsibility Commercial Series. The series of commercials incorporates clear, engaging storytelling to prompt viewers to think about common retail trading behaviors—especially high-energy marketing, gamification of speculation, and heavy focus on potential gains without equal attention to risks—and to choose more thoughtful, informed approaches. Lev Mazur, Founder of Quantfury, said: “It’s a pleasure to work with Sandwich, whose visual storytelling is outstanding. Since day one, Quantfury has aimed to question and improve the standard practices in the global retail trading industry.” Adam Lisagor, Founder of Sandwich, added: “A good investment is a story. Quantfury stood out by wanting to tell a real, interesting story first—rather tha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom